BRPI1016209A2 - agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença - Google Patents

agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença

Info

Publication number
BRPI1016209A2
BRPI1016209A2 BRPI1016209A BRPI1016209A BRPI1016209A2 BR PI1016209 A2 BRPI1016209 A2 BR PI1016209A2 BR PI1016209 A BRPI1016209 A BR PI1016209A BR PI1016209 A BRPI1016209 A BR PI1016209A BR PI1016209 A2 BRPI1016209 A2 BR PI1016209A2
Authority
BR
Brazil
Prior art keywords
disease
treating
targeting agent
lymphocyte targeting
lymphocyte
Prior art date
Application number
BRPI1016209A
Other languages
English (en)
Inventor
Carsten TSCHÖPE
Felicitas Escher
H-P Schultheiss
Hans-Dieter Volk
Petra Reinke
Original Assignee
Charité Universitätsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charité Universitätsmedizin Berlin filed Critical Charité Universitätsmedizin Berlin
Publication of BRPI1016209A2 publication Critical patent/BRPI1016209A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
BRPI1016209A 2009-04-16 2010-04-16 agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença BRPI1016209A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09005424 2009-04-16
PCT/EP2010/002362 WO2010118890A1 (en) 2009-04-16 2010-04-16 B-lymphocyte targeting agents for use in a method for the treatment of a disease

Publications (1)

Publication Number Publication Date
BRPI1016209A2 true BRPI1016209A2 (pt) 2016-11-08

Family

ID=42235705

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1016209A BRPI1016209A2 (pt) 2009-04-16 2010-04-16 agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença

Country Status (8)

Country Link
US (1) US10144777B2 (pt)
EP (1) EP2419449A1 (pt)
JP (1) JP5863115B2 (pt)
CN (1) CN102395602B (pt)
AU (1) AU2010237272B2 (pt)
BR (1) BRPI1016209A2 (pt)
CA (1) CA2758585A1 (pt)
WO (1) WO2010118890A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2773221B1 (en) * 2011-11-04 2019-01-09 Bio-Rad Laboratories, Inc. Simultaneous purification of cell components
US9766207B2 (en) 2011-11-04 2017-09-19 Bio-Rad Laboratories, Inc. Affinity methods and compositions employing electronic control of pH
EP2814597A4 (en) 2012-02-15 2015-10-28 Bio Rad Laboratories ELECTRONIC CONTROL OF PH-VALUE AND ION STRENGTH
US9321012B2 (en) 2012-04-04 2016-04-26 Bio-Rad Laboratories, Inc. Electronic protein fractionation
CN107635585A (zh) * 2015-03-06 2018-01-26 分析科学莱布尼茨研究所Isas协会 心力衰竭的治疗和预防中的rkip激动

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0932417B1 (en) 1996-10-17 2003-03-05 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
MXPA06011805A (es) * 2004-04-16 2006-12-15 Genentech Inc Metodo para aumentar agotamiento de celulas b.
US20070009518A1 (en) * 2005-05-18 2007-01-11 Biogen Idec Inc. Methods for treating fibrotic conditions
MX2007014497A (es) * 2005-05-20 2008-02-07 Genentech Inc Pretratamiento de una muestra biologica de un sujeto con enfermedad autoinmune.
EP1904101A4 (en) 2005-06-08 2011-06-15 Univ Duke ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
CN103694349A (zh) * 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用

Also Published As

Publication number Publication date
AU2010237272B2 (en) 2015-07-09
US20120100069A1 (en) 2012-04-26
AU2010237272A1 (en) 2011-11-10
CA2758585A1 (en) 2010-10-21
JP2012524037A (ja) 2012-10-11
WO2010118890A1 (en) 2010-10-21
CN102395602A (zh) 2012-03-28
JP5863115B2 (ja) 2016-02-16
EP2419449A1 (en) 2012-02-22
US10144777B2 (en) 2018-12-04
CN102395602B (zh) 2017-10-24

Similar Documents

Publication Publication Date Title
BRPI0815760A2 (pt) Composição dermatológica injetável para o tratamento de rugas
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
SG10201503135RA (en) Agent for treating disease
IL207892A0 (en) Agent for treating disease
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
IL207891A0 (en) Agent for treating disease
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BR112013018679A2 (pt) agente para o tratamento da alopecia
BRPI0821145A2 (pt) Agente terapêutico para prurido
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BR112012027145A2 (pt) emulsão, composição de uso final e método para tratar uma condição cutânea
BRPI1013509A2 (pt) método e composição para melhorar a absorção de agentes terapêuticos
BRPI0719523A2 (pt) Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
BRPI0918401A2 (pt) método para seletivamente aquecer uma linha de agente redutor
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BRPI1016209A2 (pt) agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer
BRPI0907723A2 (pt) Métodos e composições para o tratamento de doença respiratória
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 10A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2562 DE 11/02/2020.